A primary immune response occurs when the adaptive immune system first encounters an antigen; a secondary response occurs on later exposure to the same or a related antigen. The secondary response is usually faster, larger, longer-lasting and more effective because antigen-specific memory B and T cells were generated during the first response. Innate immunity responds immediately at both encounters and helps determine the quality of the adaptive response.
At a glance
| Feature | Primary response | Secondary response |
|---|---|---|
| Responding cells | Naive B and T lymphocytes | Memory B/T cells plus newly recruited cells |
| Lag phase | Longer—days while clones activate | Shorter |
| Magnitude | Lower | Higher |
| Antibody | IgM appears first, then class-switched antibody | Usually faster, higher-affinity IgG/IgA/IgE depending on site and response |
| Duration | Shorter | Longer due to memory and long-lived plasma cells |
Learning outcomes
The learner should be able to describe the stages of a primary adaptive response, explain how memory cells produce a secondary response, distinguish primary and secondary antibody patterns, relate responses to vaccination and serology, identify factors that weaken memory, and apply the concepts to infection, immunisation and emergency care.
1. What starts an immune response?
An antigen is a molecule recognised by immune receptors. Pathogen-associated and damage-associated signals activate innate cells, which release cytokines and increase co-stimulatory molecules. Dendritic cells capture antigen in tissues and migrate to lymph nodes, where they present peptide fragments to naive T cells.
The adaptive response requires more than antigen recognition. A T cell needs antigen displayed on an appropriate major histocompatibility complex (MHC) molecule plus co-stimulation and cytokine signals. This protects against inappropriate activation and contributes to peripheral tolerance.
2. The primary immune response
2.1 Recognition and antigen presentation
- Dendritic cells process proteins and present peptides on MHC class II to CD4 T cells and, through cross-presentation, selected antigens on MHC class I to CD8 T cells.
- Naive lymphocytes circulate through secondary lymphoid organs until their receptors encounter the appropriate antigen.
- Co-stimulation and cytokines determine whether cells become helper, cytotoxic, regulatory or memory populations.
2.2 Clonal selection and expansion
Only the rare B or T cell with a receptor that fits the antigen is selected. It proliferates into a clone. This explains specificity: thousands of different clones exist before infection, but only a small subset responds to each antigen.
2.3 B-cell activation
B cells bind native antigen through the B-cell receptor, internalise it and present peptide to helper T cells. CD40–CD40L interaction and cytokines support proliferation and differentiation. Some responses to repetitive polysaccharides can be T-independent and generate weaker memory, especially in young children.
2.4 Germinal-centre reaction
Activated B cells enter follicles and form germinal centres. They undergo somatic hypermutation and selection for higher-affinity receptors, then class-switch recombination from IgM to IgG, IgA or IgE according to cytokine and tissue signals. The result is affinity maturation and long-lived plasma or memory B cells.
2.5 T-cell activation
- CD4 helper cells: Th1 cells activate macrophages and support intracellular pathogen control; Th2 cells support eosinophils and IgE; Th17 cells recruit neutrophils and strengthen mucosal defence; T follicular helper cells support germinal centres; regulatory T cells limit damage.
- CD8 cytotoxic cells: recognise peptide on MHC I and kill infected or abnormal cells through perforin/granzyme and death-receptor pathways.
3. Primary response kinetics
| Phase | What happens | Clinical/serological meaning |
|---|---|---|
| Lag | Antigen capture, lymphocyte activation and clonal expansion | Tests may be negative early; symptoms may precede detectable antibody |
| Log/exponential | Rapid proliferation and antibody/cytokine production | Antibody titre rises; symptoms may peak |
| Plateau | Effector response balances antigen persistence and clearance | Clinical improvement may begin |
| Decline | Most effector cells die after antigen removal | Antibody wanes, but memory cells and long-lived plasma cells remain |
The exact time course varies by antigen, dose, route, adjuvant, host age and immune status. A negative early antibody test does not always exclude infection.
4. The secondary immune response
4.1 Memory cell activation
Memory B and T cells are more numerous, have lower activation thresholds and are distributed through lymphoid and peripheral tissues. On re-exposure, they respond with less delay and can recruit additional innate and adaptive cells.
4.2 Faster and stronger antibody response
Memory B cells rapidly become plasma cells. Because many underwent affinity maturation and class switching, the response often contains higher-affinity IgG or mucosal IgA rather than predominantly IgM. Long-lived plasma cells in bone marrow can maintain baseline antibody for years.
4.3 Faster cellular response
Memory CD4 and CD8 cells produce cytokines and cytotoxic effects rapidly. Tissue-resident memory cells can respond at the portal of entry before the pathogen disseminates.
4.4 Why secondary protection may fail
- Antigenic drift or a different strain is poorly recognised.
- Memory has waned or was never generated adequately.
- Immunosuppression, malnutrition, extremes of age or severe illness weaken the response.
- The pathogen evades immunity or establishes a protected reservoir.
- Antibody prevents severe disease but not all infection or transmission.
5. Tertiary and repeated responses
Third and later exposures can produce progressively more mature memory responses, although the pattern depends on antigen variation and immune regulation. Repeated vaccination may broaden or increase antibody titres, but more doses are not automatically better; schedules are based on evidence, age, risk and vaccine characteristics.
6. Primary versus secondary response in serology
| Pattern | Typical interpretation | Caution |
|---|---|---|
| Early IgM then IgG | Possible recent primary response | IgM can persist, cross-react or be absent; timing and assay matter |
| High-affinity IgG or rising titre | Previous exposure, vaccination or secondary response | Does not always prove current infection |
| Paired sera with significant rise | Evidence of recent infection in selected tests | Requires validated timing and laboratory interpretation |
| No detectable antibody | No exposure, early window period or impaired response | Consider repeat testing, PCR/antigen test or cellular assays as appropriate |
Serology should be interpreted with symptoms, exposure, vaccination history, local epidemiology and the test’s sensitivity and specificity. Do not diagnose or exclude an emergency solely from antibody status.
7. Vaccination and immune memory
Vaccines expose the immune system to a safe antigenic form or genetic instruction so that memory can develop without the full disease. Primary vaccination generates the initial response; booster doses recall memory and may increase antibody quantity, affinity and durability.
7.1 Factors influencing vaccine response
- Antigen type, dose, route, adjuvant and schedule.
- Age, pregnancy, malnutrition, chronic disease and immunosuppressive medicines.
- Prior infection or vaccination and the antigenic match to circulating strains.
- Cold-chain integrity, correct administration and time to develop immunity.
7.2 Vaccine protection is not all-or-none
Memory can reduce severe disease even when it does not prevent infection. A vaccinated patient with fever still needs appropriate assessment; vaccination history changes probabilities but does not eliminate differential diagnoses.
8. Maternal and neonatal immunity
Maternal IgG crosses the placenta and provides temporary neonatal protection. Secretory IgA in breast milk supports mucosal defence but does not replace the infant’s own vaccination schedule. Maternal antibodies can also interfere with responses to some live vaccines, which is one reason schedules are age-specific.
9. Factors that impair primary and secondary responses
| Factor | Effect | Clinical implication |
|---|---|---|
| Infancy/older age | Immature or immunosenescent responses | Different vaccine timing, titres and infection risk |
| HIV or T-cell deficiency | Poor helper function and weak memory | Opportunistic infection and altered vaccine decisions |
| B-cell/antibody deficiency | Reduced humoral protection | Recurrent bacterial or encapsulated-organism infection |
| Malnutrition | Reduced lymphocyte proliferation and barrier function | Severe infection and poor vaccine response |
| Corticosteroids/chemotherapy | Suppressed proliferation or cytokine signalling | Timing and vaccine safety require specialist review |
| Asplenia | Reduced clearance of encapsulated bacteria | Urgent fever evaluation and specific vaccination/prophylaxis plans |
| Antigenic variation | Memory recognition is less effective | Reinfection or breakthrough illness |
10. Clinical applications
10.1 Reinfection versus relapse
A stronger secondary response can shorten illness after reinfection, but persistence of a pathogen or inadequate clearance may cause relapse. Use clinical course, microbiology and imaging rather than antibody titres alone.
10.2 Booster decisions
Boosters are used when protection wanes, the pathogen changes, the initial series was incomplete or a high-risk exposure occurs. The correct schedule depends on national policy and individual risk.
10.3 Passive versus active protection
Vaccination creates active immune memory. Immunoglobulin or monoclonal antibody provides passive, immediate but temporary protection and does not create the same memory response. In some exposures both are indicated.
11. Emergency relevance
Severe infection
- Do not wait for antibody maturation in sepsis, meningitis, pneumonia or anaphylaxis.
- Use ABCDE, cultures when appropriate, antimicrobials and supportive care according to protocol.
Immunocompromised patient
- Assume atypical presentations and reduced vaccine protection are possible.
- Ask about HIV, chemotherapy, steroids, transplant, asplenia and immunoglobulin therapy.
Post-exposure care
- Determine timing, prior vaccination, exposure intensity and whether passive immunisation is required.
- Document counselling, follow-up testing and return precautions.
12. Case applications
Case 1: Early negative serology
A patient presents shortly after exposure with compatible symptoms but a negative antibody test. The lag phase may precede detectable antibody. Use the appropriate direct pathogen test, repeat serology at the recommended interval and treat urgent illness immediately.
Case 2: Breakthrough infection after vaccination
A vaccinated patient develops respiratory symptoms during circulation of a variant. Memory may reduce severity without preventing infection. Assess oxygenation and complications normally, and use the recommended pathogen test.
Case 3: Fever in an asplenic patient
An asplenic patient has fever and rigors despite prior vaccination. Vaccines reduce risk but do not eliminate it. Treat fever as a medical emergency, obtain cultures when safe and start protocol-directed antimicrobials promptly.
13. Exam pearls
- Primary responses involve naive lymphocytes and have a longer lag; secondary responses involve memory cells and are faster and stronger.
- IgM often appears first in a primary response, followed by class-switched antibody; secondary responses commonly have high-affinity IgG or mucosal IgA.
- Affinity maturation and class switching occur in germinal centres with T-cell help.
- Vaccination aims to create memory, not merely a temporary antibody level.
- A normal or negative antibody test may reflect early timing, absent marker production or impaired immunity.
- Passive immunoglobulin gives immediate temporary protection but does not produce durable memory.
Quick self-test
- What is the key difference between primary and secondary immune responses?
- Why is the secondary antibody response usually higher affinity?
- What roles do memory B and T cells play?
- Why can a vaccinated person still become infected?
- What factors can make a vaccine response weak?
Answers
- Primary responses activate naive lymphocytes and take longer; secondary responses recall memory cells and are faster, larger and longer-lasting.
- Activated B cells undergo somatic hypermutation and selection in germinal centres.
- Memory B cells rapidly produce high-affinity antibody; memory T cells provide rapid helper or cytotoxic responses.
- Antigenic variation, waning or incomplete immunity, immune compromise and vaccine limitations can allow infection even when severe disease is reduced.
- Age, malnutrition, HIV or other immune deficiency, immunosuppressive medicines, chronic disease, incorrect schedule, poor storage and pathogen variation.
References and further reading
- NCBI Bookshelf: Immunological memory.
- NCBI Bookshelf: Immune response physiology.
- NCBI Bookshelf: Humoral immune response.
- NCBI Bookshelf: T-cell-mediated immunity.
- Follow national immunisation, post-exposure prophylaxis and infectious-disease protocols.
